Company Overview

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for neurological and neuropsychiatric diseases. The company operates within the biotechnology and pharmaceuticals industries, with an emphasis on conditions involving glutamate dysregulation, protein misfolding, and neuroinflammation. Its core value proposition centers on advancing differentiated, mechanism-based drug candidates targeting areas of high unmet medical need.

Biohaven’s primary business activities are research and development rather than commercial sales, and its revenue has historically consisted mainly of collaboration payments, milestone receipts, and investment income. The company is best known for its historical role in developing migraine therapies, including rimegepant, before a strategic transaction reshaped its corporate structure. Biohaven Ltd. was established following the 2022 sale of Biohaven Pharmaceutical Holding Company’s CGRP migraine portfolio to Pfizer, allowing the remaining entity to focus on earlier-stage neuroscience assets.

Business Operations

Biohaven’s operations are organized around a pipeline of clinical and preclinical drug candidates, with its most advanced programs targeting neurodegenerative and neuropsychiatric disorders. Key development programs include troriluzole for spinocerebellar ataxia and obsessive-compulsive disorder, and BHV-7000, a selective Kv7 potassium channel activator for epilepsy and mood disorders. These programs represent the company’s principal operational focus and cost drivers.

The company conducts research through a combination of internal capabilities and outsourced clinical development, relying on contract research organizations for trials conducted in both the United States and international markets. Biohaven operates through wholly owned subsidiaries, including Biohaven Pharmaceuticals, Inc., which supports its R&D and corporate functions. As a clinical-stage company, Biohaven does not maintain manufacturing operations at commercial scale.

Strategic Position & Investments

Biohaven’s strategy centers on advancing late-stage clinical assets while selectively expanding its pipeline through internal research and external opportunities. Following the Pfizer transaction, the company retained a strong balance sheet relative to its size, enabling continued investment in multiple parallel development programs. Management has emphasized disciplined capital allocation and a focus on assets with clear regulatory and commercial pathways.

The company has made targeted acquisitions and licensing arrangements to bolster its neuroscience portfolio, including the acquisition of channel-modulating and glutamate-pathway technologies. Biohaven’s strategic positioning is anchored in neurological disorders where existing treatments are limited or inadequately effective, with an emphasis on differentiated mechanisms of action rather than incremental improvements.

Geographic Footprint

Biohaven is headquartered in the United States, with its principal executive offices in New Haven, Connecticut. The company’s operational footprint is primarily U.S.-based, reflecting its concentration on research, development, and corporate management activities.

Despite its domestic headquarters, Biohaven maintains an international presence through global clinical trials conducted across North America, Europe, and select other regions. This international reach supports patient recruitment, regulatory engagement, and future commercialization planning, although the company does not currently operate large-scale foreign subsidiaries or manufacturing facilities.

Leadership & Governance

Biohaven was founded by physician-scientists with deep expertise in neurology and drug development, a background that continues to influence its research-driven culture. The leadership team emphasizes scientific rigor, capital discipline, and long-term value creation through innovation in complex neurological diseases.

Key executives include:

• Vlad Coric – President and Chief Executive Officer
• Eric J. Jacobson – Chief Financial Officer
• Christian Walker – Chief Medical Officer
• Richard A. Bianco – Chief Development Officer
• Susan Sweeney – Chief Operating Officer

The company is governed by a board of directors with experience across biopharmaceutical development, capital markets, and corporate governance, aligning oversight with Biohaven’s strategic focus on late-stage clinical execution and risk management.